Karyopharm Therapeutics Inc. (KPTI)

8.70
NASDAQ : Health Technology
Prev Close 9.16
Day Low/High 8.64 / 9.41
52 Wk Low/High 3.92 / 21.71
Avg Volume 2.42M
Exchange NASDAQ
Shares Outstanding 61.92M
Market Cap 567.20M
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Karyopharm Announces Publication Of XPOVIO™ (Selinexor) Phase 2b STORM Study Results In The New England Journal Of Medicine

Karyopharm Announces Publication Of XPOVIO™ (Selinexor) Phase 2b STORM Study Results In The New England Journal Of Medicine

-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody -- -- In STORM, XPOVIO Achieved a 26%...

ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors Of Important Deadline In Securities Class Action; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - KPTI

ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors Of Important Deadline In Securities Class Action; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - KPTI

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Karyopharm Therapeutics Inc.

Notable Two Hundred Day Moving Average Cross - KPTI

Notable Two Hundred Day Moving Average Cross - KPTI

In trading on Tuesday, shares of Karyopharm Therapeutics Inc crossed below their 200 day moving average of $7.64, changing hands as low as $7.55 per share. Karyopharm Therapeutics Inc shares are currently trading down about 1.4% on the day.

Karyopharm Reports Second Quarter 2019 Financial Results And Highlights Recent Company Progress

Karyopharm Reports Second Quarter 2019 Financial Results And Highlights Recent Company Progress

− XPOVIO™ Commercial Launch Underway Following July 3 rd FDA Accelerated Approval − − XPOVIO is the First and Only Prescription Medicine Approved in the U.

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - KPTI

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - KPTI

NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc.

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors To Contact The Firm

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors To Contact The Firm

SAN DIEGO, Aug. 2, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below.

Karyopharm To Report Second Quarter 2019 Financial Results On August 6, 2019

Karyopharm To Report Second Quarter 2019 Financial Results On August 6, 2019

-- Conference Call Scheduled for Tuesday, August 6, 2019 at 8:30 a.m. ET --

Rosen, A Top Ranked Law Firm, Announces Filing Of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.

Rosen, A Top Ranked Law Firm, Announces Filing Of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc.

First Week Of KPTI September 20th Options Trading

First Week Of KPTI September 20th Options Trading

Investors in Karyopharm Therapeutics Inc saw new options begin trading this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI

KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI

NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.

Lifshitz & Miller LLP Announces Investigation Of Choice Bancorp, Inc., Eagle Bancorp, Inc., EQT Corporation, Highpower International, Inc., Karyopharm Therapeutics Inc., MicroStrategy Incorporated Investors, Pintec Technology Holdings Limited Investors, And Speedway Motorsports, Inc.

Lifshitz & Miller LLP Announces Investigation Of Choice Bancorp, Inc., Eagle Bancorp, Inc., EQT Corporation, Highpower International, Inc., Karyopharm Therapeutics Inc., MicroStrategy Incorporated Investors, Pintec Technology Holdings Limited Investors, And Speedway Motorsports, Inc.

NEW YORK, July 26, 2019 /PRNewswire/ -- Choice Bancorp, Inc. (CBKW) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of Choice to Nicolet Bankshares, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

NEW YORK, July 26, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc.

KPTI INVESTOR ALERT: Hagens Berman Alerts Investors In Karyopharm Therapeutics (KPTI) Public Offerings To Possible Disclosure Violations

KPTI INVESTOR ALERT: Hagens Berman Alerts Investors In Karyopharm Therapeutics (KPTI) Public Offerings To Possible Disclosure Violations

SAN FRANCISCO, July 24, 2019 /PRNewswire/ --  Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.

KPTI CLASS ACTION ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics Inc.

KPTI CLASS ACTION ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics Inc.

NEW YORK, July 24, 2019 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc.

Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Karyopharm Therapeutics Inc. And Certain Of Its Senior Executives, Its Board Of Directors, And Underwriters Of Its April 2017 And May 2018 Stock Offerings

Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Karyopharm Therapeutics Inc. And Certain Of Its Senior Executives, Its Board Of Directors, And Underwriters Of Its April 2017 And May 2018 Stock Offerings

NEW YORK, July 23, 2019 /PRNewswire/ -- Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") today announced that it filed a securities class action lawsuit on behalf of its client Allegheny County Employees' Retirement System ("ACERS") against Karyopharm...

2 Attractive Biotechs With Key Study Outcomes on the Horizon

2 Attractive Biotechs With Key Study Outcomes on the Horizon

Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.

Karyopharm Announces FDA Approval Of XPOVIO™ (selinexor) For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

Karyopharm Announces FDA Approval Of XPOVIO™ (selinexor) For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome...

First Week Of February 2020 Options Trading For Karyopharm Therapeutics (KPTI)

First Week Of February 2020 Options Trading For Karyopharm Therapeutics (KPTI)

Investors in Karyopharm Therapeutics Inc saw new options begin trading this week, for the February 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Notable Monday Option Activity: KPTI, CASA, WYNN

Notable Monday Option Activity: KPTI, CASA, WYNN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Karyopharm Therapeutics Inc , where a total volume of 11,447 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 112.1% of KPTI's average daily trading volume over the past month, of 1.0 million shares.

Relative Strength Alert For Karyopharm Therapeutics

Relative Strength Alert For Karyopharm Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Karyopharm Announces FDA Extension Of Review Period For Selinexor New Drug Application

Karyopharm Announces FDA Extension Of Review Period For Selinexor New Drug Application

- PDUFA Action Date Extended by Three Months to July 6, 2019 -

Take a Poker Player's Approach to Playing Small Biotech Stocks

Take a Poker Player's Approach to Playing Small Biotech Stocks

As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.

Relative Strength Alert For Karyopharm Therapeutics

Relative Strength Alert For Karyopharm Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of December 21st Options Trading For Karyopharm Therapeutics (KPTI)

First Week Of December 21st Options Trading For Karyopharm Therapeutics (KPTI)

Investors in Karyopharm Therapeutics Inc saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new December 21st contracts and identified the following put contract of particular interest.

Karyopharm Therapeutics Enters Oversold Territory (KPTI)

Karyopharm Therapeutics Enters Oversold Territory (KPTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting KPTI Put And Call Options For May 2019

Interesting KPTI Put And Call Options For May 2019

Investors in Karyopharm Therapeutics Inc saw new options begin trading this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D (Sell)